Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TPST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — The CFO resigned effective immediately for personal reasons, triggering the departure-of-CFO red flag.
Tempest Therapeutics CFO Constance Ames resigns immediately; Stephanie Horn-Warnock appointed CFO
Filed October 30, 2026 · Period ending October 26, 2026 · ~1 min read
Key Changes
-
high
CFO Constance Ames resigned effective immediately on October 26, 2026, citing personal considerations unrelated to the company.
Item 5.02 verify on EDGAR → -
high
Stephanie Horn-Warnock was appointed CFO, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary effective immediately.
Item 5.02 verify on EDGAR → -
medium
Horn-Warnock will initially serve as a consultant at $450 per hour plus expenses and a 5.0% indirect cost allocation, rather than as a direct employee.
Item 5.02 verify on EDGAR →
Summary
Tempest Therapeutics disclosed that Chief Financial Officer Constance Ames resigned effective immediately on October 26, 2026, for personal considerations unrelated to the company. The sudden departure left the CFO role vacant until the board appointed Stephanie Horn-Warnock to the position, also effective immediately. Horn-Warnock brings over 14 years of accounting and financial management experience, including public accounting at BDO USA.
The immediate resignation of a CFO is a notable governance event for a small biotech, as it removes a key financial leader without a transition period. The company moved quickly to fill the role, but the new CFO will initially serve as a consultant at $450 per hour plus expenses and a 5.0% indirect cost allocation, rather than as a direct employee. This consulting arrangement may reflect a transitional or cost-conscious approach, and investors should consider the implications for financial leadership stability.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Ms. Constance Ames confirmed to Tempest Therapeutics, Inc. (the “Company”) that she would be resigning from her position as Chief Financial Officer of the Company and from any and all other positions she holds with the Company for personal considerations unrelated to the Company, effective immediately.
The company's CFO resigned effective immediately on October 26, 2026, citing personal considerations unrelated to the company. This is a sudden departure with no transition period, which can be disruptive for a small biotech.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Nov 2, 2026 · How we verify